These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25777185)

  • 21. Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.
    Dentone C; Sterrantino G; Signori A; Cenderello G; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Giacomini M; Bruzzone B; Francisci D; Di Biagio A;
    Int J STD AIDS; 2017 Oct; 28(11):1067-1073. PubMed ID: 28142395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
    Towner W; Lalezari J; Sension MG; Wohlfeiler M; Gathe J; Appelbaum JS; Bellman P; Gottlieb MS; Ryan R; Nijs S; Hoogstoel A; Van Solingen-Ristea R; Witek J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):614-8. PubMed ID: 20134329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
    Willig JH; Wilkins SA; Tamhane A; Nevin CR; Mugavero MJ; Raper JL; Napolitano LA; Saag MS
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):105-11. PubMed ID: 22881368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
    Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
    AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
    Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
    Taiwo BO; Chan ES; Fichtenbaum CJ; Ribaudo H; Tsibris A; Klingman KL; Eron JJ; Berzins B; Robertson K; Landay A; Ofotokun I; Brown T;
    Clin Infect Dis; 2015 Oct; 61(7):1179-88. PubMed ID: 26060295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
    van Lelyveld SF; Symons J; van Ham P; Connell BJ; Nijhuis M; Wensing AM; Hoepelman AI
    Int J Antimicrob Agents; 2016 Jan; 47(1):84-90. PubMed ID: 26585497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
    Nozza S; Galli L; Bigoloni A; Nicola G; Pogliaghi M; Cossarini F; Salpietro S; Galli A; Della Torre L; Tambussi G; Lazzarin A; Castagna A
    J Acquir Immune Defic Syndr; 2011 Apr; 56(4):e113-5. PubMed ID: 21350358
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
    Soulie C; Peytavin G; Charpentier C; Lambert-Niclot S; Sayon S; Visseaux B; Simon A; Katlama C; Yazdanpanah Y; Descamps D; Calvez V; Marcelin AG
    AIDS Res Hum Retroviruses; 2015 May; 31(5):475-8. PubMed ID: 25420695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maraviroc.
    Carter NJ; Keating GM
    Drugs; 2007; 67(15):2277-88; discussion 2289-90. PubMed ID: 17927288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
    J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials.
    Nelson M; Fisher M; Gonzalez-Garcia J; Rockstroh JK; Weinstein D; Valdez H; Mayer H; van der Ryst E; Goodrich JM; Dang N
    HIV Clin Trials; 2010; 11(3):145-55. PubMed ID: 20736151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
    Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
    Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
    AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.